VYNE Therapeutics Inc. (VYNE)

Market Cap	19.28M
Revenue (ttm)	605,000
Net Income (ttm)	-42.20M
Shares Out	14.83M
EPS (ttm)	-0.99
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	219,304
Open	1.375
Previous Close	1.370
Day's Range	1.280 - 1.395
52-Week Range	1.270 - 4.300
Beta	1.77
Analysts	Strong Buy
Price Target	6.25 (+380.77%)
Earnings Date	May 8, 2025

About VYNE

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company’s lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control a...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 25, 2018
• Employees: 13
• Stock Exchange: NASDAQ
• Ticker Symbol: VYNE
• Website: https://vynetherapeutics.com

Financial Performance

In 2024, VYNE Therapeutics's revenue was $501,000, an increase of 18.16% compared to the previous year's $424,000. Losses were -$39.83 million, 39.3% more than in 2023.

Analyst Forecast

According to 2 analysts, the average rating for VYNE stock is "Strong Buy." The 12-month stock price forecast is $6.25, which is an increase of 380.77% from the latest price.

Price Target

$6.25

(380.77% upside)

Analyst Consensus: Strong Buy